1A9B5D3A-CEB0-4225-9C3D-CBE98A007A3A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.465177398160314
- age_years
- 60
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.540
- G2M_CHECKPOINT+0.496
- INTERFERON_GAMMA_RESPONSE+0.469
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.454
- TGF_BETA_SIGNALING+0.452
- UNFOLDED_PROTEIN_RESPONSE+0.446
- MYC_TARGETS_V1+0.444
- MTORC1_SIGNALING+0.439
- INTERFERON_ALPHA_RESPONSE+0.436
- E2F_TARGETS+0.435
Top 10 suppressed
- KRAS_SIGNALING_DN-0.439
- PANCREAS_BETA_CELLS-0.362
- SPERMATOGENESIS-0.299
- MYOGENESIS-0.173
- ESTROGEN_RESPONSE_LATE-0.035
- ESTROGEN_RESPONSE_EARLY+0.032
- BILE_ACID_METABOLISM+0.053
- WNT_BETA_CATENIN_SIGNALING+0.064
- UV_RESPONSE_UP+0.078
- APICAL_SURFACE+0.086
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.976 |
| 2 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.970 |
| 3 | SRR934730 | — | — | 0.970 |
| 4 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.961 |
| 5 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.960 |
| 6 | SRR934907 | — | — | 0.959 |
| 7 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.959 |
| 8 | SRR934860 | — | — | 0.958 |
| 9 | SRR934913 | — | — | 0.957 |
| 10 | SRR934921 | — | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.540 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.496 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.469 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.454 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.452 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.446 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.444 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.439 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.436 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.435 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.425 | Idelalisib | — uncovered |
| APOPTOSIS | 0.401 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.399 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.383 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.372 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.365 | Inavolisib | — uncovered |
| COMPLEMENT | 0.362 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.361 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.348 | Inavolisib | — uncovered |